Ovarian cancer (BRCA-mutated)
- Platinum sensitivity is often high
- PARP inhibitors exploit homologous-recombination deficiency
- Maintenance PARP therapy is important in selected settings
- Benefit/risk depends on prior therapy + disease context
- Monitor cytopenias and rare MDS/AML risk
- Germline BRCA finding requires family/genetic counseling
Use at a glance
- Platinum sensitivity is often high
Choosing treatment
- Maintenance PARP therapy is important in selected settings
Practical pearls
- PARP inhibitors exploit homologous-recombination deficiency
- Germline BRCA finding requires family/genetic counseling
Monitoring / follow-up
- Benefit/risk depends on prior therapy + disease context
- Monitor cytopenias and rare MDS/AML risk
Self-check
- Which hematologic risks are monitored in BRCA ovarian cancer therapy?
Cytopenias and rare MDS/AML risk. - What does a germline BRCA finding in ovarian cancer require?
Family/genetic counseling.
Drugs used for this (1)
All clinical uses · Open Ovarian cancer (BRCA-mutated) in the interactive console ↗